Folletos Novo Nordisk

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

Barron's on MSN · 1d

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on the Way.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Investopedia on MSN · 1d

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce treatments using Zealand's experimental petrelintide injectable.

8don MSN

Novo Nordisk slashes Wegovy price for patients lacking insurance benefits

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

The Motley Fool28d

Why Novo Nordisk Stock Keeps Going Down

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

The Hill8d

Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Trending now